Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma

NCT04195958 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04195958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04195958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2020
Completion date
October 18, 2021
Enrollment
3 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe allergic asthma